Last reviewed · How we verify
TOK-001
At a glance
| Generic name | TOK-001 |
|---|---|
| Also known as | Dose Group 1, Dose Group 3, Dose Group 4, Dose Group 2, Dose Group 5 |
| Sponsor | LTN PHARMACEUTICALS, INC. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC (PHASE3)
- A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer (PHASE2)
- ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |